Fair Value Calculator Fair Value Calculator
EN DE

AfroCentric Investment Corporation (ACT) Fair Value & Analysis

Healthcare · ZA · Market cap 655M ZAC

AI AfroCentric Investment Corporation ACT · JSE
PriceR0.8000
Fair ValueR3.14
Upside+292.5%
Quality39/100
Watch AfroCentric Investment Corporation for free, get notified when fair value or trend changes. Watch for free
Evidence: High Range R2.31 – R3.96 📤 Share as image

Fair value as of: Jul 19, 2026

From 15 valuation models · updated yesterday

Fair value updated Jul 19, 2026, revised from R11.37 to R3.14 (−72.4%) since Jun 26, 2026. Share price −7.0% over the past month.

Price vs Fair Value (12 months)

R1.75 R0.7000 Fair Value R3.14 Jul 2025 Jul 2026

12‑month range R0.7000 – R1.75 · fair‑value band R2.31 – R3.96 · the R0.8000 price screens below the R3.14 fair value. As of Jul 19, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

AfroCentric Investment Corporation (ACT) currently trades at R0.8000, while our model-based Fair Value estimate is R3.14, implying the stock looks roughly 292.5% undervalued today. We read business quality at 39/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, AfroCentric Investment Corporation generated revenue of 7.5B ZAR at a net margin of -17.1%. Revenue declined 2.6% year over year. It earns a return on equity of -24.7%. Net debt stands at 136M ZAR. Fundamentals as of Jul 19, 2026

Our scenario range runs from R2.31 (bear case) to R3.96 (bull case); at R0.8000, the current price sits below that range. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at 293%, ACT screens cheaper than that median.

Key figures & financial health

Revenue (TTM) 7.5B ZAC
Revenue growth (YoY) -2.6%
Net margin -17.1%
Return on equity -24.7%
Free cash flow 466M ZAC FY2026
Operating margin 29.2%
More key figures
EPS (TTM) R-0.7900
EPS growth (YoY) -3.4%
Net debt 136M ZAC FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.

About the company

AfroCentric Investment Corporation Limited, an investment holding company, provides healthcare products and services to private and public sectors in South Africa and internationally. The company operates through Healthcare SA, Healthcare Retail, Healthcare Africa, and Information Technology segments. It offers health administration, health risk management, medical scheme administration, marketing and distribution, as well as specialized and technology-based products and services; HIV/AIDS management; DBC equipment and administration services to musculoskeletal treatment centres; and dental management services. The company also engages in the manufacture, distribution, marketing, and retail of medicines and pharmaceutical products under the Pharmacy Direct, Curasana, Activo Health, and Scriptpharm brand names. In addition, it provides health insurance products for individuals and organisations; occupational health programmes; administration services for a market of medical schemes, …

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

AfroCentric Investment Corporation reported revenue of R7.3B in FY2026 versus R8.7B in FY2022, a compound −4.3%/yr. Reported net income was −R1.3B in FY2026.

Revenue −4.3%/yr
FY22 R8.7B
FY23 R8.8B
FY24 R8.8B
FY25 R8.5B
FY26 R7.3B
Net income
FY22 R313M
FY23 R184M
FY24 R55.4M
FY25 −R28.8M
FY26 −R1.3B

Is ACT fairly valued? → Check now

📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog, it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "AfroCentric Investment Corporation Fair Value". https://www.fairvalue-calculator.com/stock/ACT.JSE

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc H1CA34 R$95.75 R$123.65 +29%
Fresenius SE FRE €37.69 €30.03 -20%
IHH Healthcare Berhad, an investment holding company, Q0F 2.76 SGD 1.28 SGD -54%
Tenet Healthcare Corporation THC $164.77 $280.85 +70%
Rede D'Or São Luiz S.A RDOR3 R$32.76 R$30.33 -7%
DaVita Inc DVAI34 R$1,081 R$207.69 -81%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,305 ₹2,546 -69%
Fresenius Medical Care AG FMS $23.59 $34.71 +47%
Aier Eye Hospital Group 300015 ¥8.54 ¥6.73 -21%
Max Healthcare Institute Limited MAXHEALTH ₹977.25 ₹283.61 -71%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is AfroCentric Investment Corporation (ACT) undervalued?
As of Jul 19, 2026, our model estimates a fair value of R3.14 versus a price of R0.8000, about +293% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ACT?
Our model-based fair value for AfroCentric Investment Corporation is R3.14 (as of Jul 19, 2026), built from audited fundamentals. The current price is R0.8000.
What is the quality score of ACT?
AfroCentric Investment Corporation has a Quality Score of 39/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of AfroCentric Investment Corporation (ACT)?
AfroCentric Investment Corporation reported trailing-twelve-month revenue of about 7.5B ZAR (latest available figure, as of Jul 19, 2026).
What is the net profit margin of ACT?
The net profit margin of AfroCentric Investment Corporation is about -17.1%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Unlock the full AfroCentric Investment Corporation analysis, and try Pro free

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.